Last reviewed · How we verify
NCT04314986
Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers
Phase 1 trial testing Cohort 1: AR882 or placebo in Healthy Volunteers in 30 participants. Completed in 18 September 2019.
18 September 2019
Quick facts
| Lead sponsor | Arthrosi Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 28 June 2019 |
| Primary completion | 18 September 2019 |
| Estimated completion | 18 September 2019 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Cohort 1: AR882 or placebo — full drug profile →
- Cohort 2: AR882 or placebo
- Cohort 3: AR882 or placebo
- Cohort 4: AR882 or placebo
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
Arthrosi Therapeutics — full company profile →
Who can join
Adults 18 to 55, male only, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study to assess multiple ascending doses of AR882 in healthy adult males.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04314986
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other Arthrosi Therapeutics trials
Trials by the same sponsor.
- NCT05253833 — Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout · Phase 2 · completed
- NCT05119686 — Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients · Phase 2 · completed
- NCT04646889 — Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment · Phase 1 · completed
- NCT04508426 — Single-dose AME Study With [14C]AR882 in Healthy Male Subjects · Phase 1 · completed
- NCT04155918 — Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04314986 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arthrosi Therapeutics
- Last refreshed: 16 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04314986.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing